Literature DB >> 23316490

Calls for more detailed studies on toxoplasmosis.

Tony Kirby.   

Abstract

Entities:  

Mesh:

Year:  2012        PMID: 23316490     DOI: 10.1016/s1473-3099(12)70303-1

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  5 in total

1.  Enhanced surveillance for toxoplasmosis in England and Wales, 2008-2012.

Authors:  K Halsby; E Guy; B Said; J Francis; C O'Connor; H Kirkbride; D Morgan
Journal:  Epidemiol Infect       Date:  2013-10-07       Impact factor: 4.434

Review 2.  Toxoplasmosis seroprevalence in Iranian women and risk factors of the disease: a systematic review and meta-analysis.

Authors:  Azadeh Mizani; Abbas Alipour; Mehdi Sharif; Shahabeddin Sarvi; Afsaneh Amouei; Azar Shokri; Mohammad-Taghi Rahimi; Seyed Abdollah Hosseini; Ahmad Daryani
Journal:  Trop Med Health       Date:  2017-04-12

3.  Screening for common eye diseases in the elderly with Optos ultra-wide-field scanning laser ophthalmoscopy: a pilot study with focus on ocular toxoplasmosis.

Authors:  Pablo Eduardo Logroño Wiese; Frank Seeber; Anne-Sophie Endres; Claudia Brockmann; Uwe Pleyer
Journal:  Int Ophthalmol       Date:  2021-03-16       Impact factor: 2.031

4.  Posterior segment findings by spectral-domain optical coherence tomography and clinical associations in active toxoplasmic retinochoroiditis.

Authors:  Justine R Smith; João M Furtado; Genevieve F Oliver; Lisia Barros Ferreira; Barbara R Vieira; Sigrid Arruda; Michelle Araújo; Jillian M Carr
Journal:  Sci Rep       Date:  2022-01-21       Impact factor: 4.379

Review 5.  Ocular toxoplasmosis: a review of the current diagnostic and therapeutic approaches.

Authors:  Dimitrios Kalogeropoulos; Hercules Sakkas; Bashar Mohammed; Georgios Vartholomatos; Konstantinos Malamos; Sreekanth Sreekantam; Panagiotis Kanavaros; Chris Kalogeropoulos
Journal:  Int Ophthalmol       Date:  2021-08-09       Impact factor: 2.031

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.